Business Description
Elite Pharmaceuticals Inc
NAICS : 325412
SIC : 2833
ISIN : US28659T2006
Total Employee Number:
68Description
Elite Pharmaceuticals Inc is a pharmaceutical company. It is principally engaged in the development and manufacture of oral, controlled-release products, using proprietary know-how and technology. The company's single operating segment is Abbreviated New Drug Applications (ANDA). The company focuses on developing pain management products; manufacturing a line of generic pharmaceutical products with approved Abbreviated New Drug Applications; developing additional generic pharmaceutical products; development of other products in its pipeline including the products with its partners; and commercialization of new products.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 5.12 | |||||
Equity-to-Asset | 0.72 | |||||
Debt-to-Equity | 0.06 | |||||
Debt-to-EBITDA | 0.1 | |||||
Interest Coverage | 126.16 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 8.54 | |||||
Beneish M-Score | -1.43 | |||||
WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 56.8 | |||||
3-Year EBITDA Growth Rate | 105.4 | |||||
3-Year EPS without NRI Growth Rate | 102.7 | |||||
3-Year Book Growth Rate | 46.9 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 54.01 | |||||
9-Day RSI | 51.5 | |||||
14-Day RSI | 51.1 | |||||
3-1 Month Momentum % | -5.45 | |||||
6-1 Month Momentum % | -25.94 | |||||
12-1 Month Momentum % | -30.82 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 6.45 | |||||
Quick Ratio | 5.22 | |||||
Cash Ratio | 1.71 | |||||
Days Inventory | 98.97 | |||||
Days Sales Outstanding | 105.2 | |||||
Days Payable | 23.77 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -2 | |||||
Shareholder Yield % | 1.28 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 50.4 | |||||
Operating Margin % | 33.56 | |||||
Net Margin % | 30.14 | |||||
EBITDA Margin % | 39.79 | |||||
FCF Margin % | 15.33 | |||||
OCF Margin % | 15.95 | |||||
ROE % | 65.61 | |||||
ROA % | 38.05 | |||||
ROIC % | 45.69 | |||||
3-Year ROIIC % | 49.9 | |||||
ROC (Joel Greenblatt) % | 85.95 | |||||
ROCE % | 54.4 | |||||
Years of Profitability over Past 10-Year | 6 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 18.43 | |||||
PE Ratio without NRI | 26.33 | |||||
Shiller PE Ratio | 1103.8 | |||||
Price-to-Owner-Earnings | 16.03 | |||||
PEG Ratio | 1.16 | |||||
PS Ratio | 2.79 | |||||
PB Ratio | 4.01 | |||||
Price-to-Tangible-Book | 4.1 | |||||
Price-to-Free-Cash-Flow | 18.43 | |||||
Price-to-Operating-Cash-Flow | 17.56 | |||||
EV-to-EBIT | 6.52 | |||||
EV-to-EBITDA | 6.3 | |||||
EV-to-Revenue | 2.51 | |||||
EV-to-FCF | 16.35 | |||||
Price-to-GF-Value | 0.66 | |||||
Price-to-Projected-FCF | 2.84 | |||||
Price-to-Median-PS-Value | 0.58 | |||||
Price-to-Peter-Lynch-Fair-Value | 0.65 | |||||
Price-to-Graham-Number | 2.17 | |||||
| Price-to-Net-Current-Asset-Value | 5.27 | |||||
Earnings Yield (Greenblatt) % | 15.34 | |||||
FCF Yield % | 5.75 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:ELTP
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Elite Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 148.87 | ||
| EPS (TTM) ($) | 0.02 | ||
| Beta | 0.794 | ||
| 3-Year Sharpe Ratio | 1.15 | ||
| 3-Year Sortino Ratio | 3.65 | ||
| Volatility % | 52.5 | ||
| 14-Day RSI | 51.1 | ||
| 14-Day ATR ($) | 0.026403 | ||
| 20-Day SMA ($) | 0.365799 | ||
| 12-1 Month Momentum % | -30.82 | ||
| 52-Week Range ($) | 0.3252 - 0.74 | ||
| Shares Outstanding (Mil) | 1,077.1 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Elite Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Elite Pharmaceuticals Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Second quarter earnings conference call for 2027 | 2026-11-17 11:30 | In 128 days | ||
| Second quarter earnings results for 2027 | 2026-11-13 | In 123 days | ||
| First quarter earnings conference call for 2027 | 2026-08-14 11:30 | In 33 days | ||
| First quarter earnings results for 2027 | 2026-08-14 | In 32 days | ||
| General meeting for 2026 | 2026-07-14 | In 1 day | ||
| Fourth quarter earnings conference call for 2026 | 2026-06-30 11:30 | 0.40 (-1.25%) | ||
| Annual report for 2026 | 2026-06-29 | 0.40 (-0.73%) | ||
| Fourth quarter earnings results for 2026 | 2026-06-29 | 0.40 (-0.73%) | ||
| Third quarter earnings conference call for 2026 | 2026-02-18 11:30 | 0.44 (-4.13%) | ||
| Third quarter earnings results for 2026 | 2026-02-17 | 0.44 (+2.80%) |
Show
Entries
Elite Pharmaceuticals Inc Frequently Asked Questions
What is Elite Pharmaceuticals Inc(ELTP)'s stock price today?
The current price of ELTP is $0.37. The 52 week high of ELTP is $0.74 and 52 week low is $0.33.
When is next earnings date of Elite Pharmaceuticals Inc(ELTP)?
The next earnings date of Elite Pharmaceuticals Inc(ELTP) is 2026-08-14 Est..
Does Elite Pharmaceuticals Inc(ELTP) pay dividends? If so, how much?
Elite Pharmaceuticals Inc(ELTP) does not pay dividend.
Guru Commentaries on OTCPK:ELTP
No articles.
Press Release
Articles on Elite Pharmaceuticals Inc
Elite Pharmaceuticals Inc (ELTP) Q4 2026 Earnings Call Highlights: Record Revenue Growth and Strategic Moves
Jul 01, 2026
Is Elite Pharmaceuticals Inc (ELTP) Undervalued After a 77% Revenue Surge? GF Score: 44/100
Jun 29, 2026
Headlines
See More- 1
Jun 30, 2026
Elite Pharmaceuticals outlines ropinirole launch next month and targets 5% to 10% of its $12M market
Seeking Alpha • 6:13pm
Jun 29, 2026
Elite Pharmaceuticals GAAP EPS of $0.03, revenue of $148.87M
Seeking Alpha • 3:32pm
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers